faculty_name,faculty_email,publication_type,title,journal,year,doi,url,file_created
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.,Blood Advances,2025,10.1182/bloodadvances.2024013656,https://experts.mcmaster.ca/display/publication3534474,2025-07-27T15:15:33.715619
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Abstract 4991: Temporal trends in health-related quality of life (HRQoL) outcomes in fourth line or higher treatment for relapsed/refractory multiple myeloma (RRMM): A systematic literature review (SLR) and meta-analysis,Cancer Research,2025,10.1158/1538-7445.am2025-4991,https://experts.mcmaster.ca/display/publication3587043,2025-07-27T15:15:33.715623
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis,Blood,2024,10.1182/blood-2024-203741,https://experts.mcmaster.ca/display/publication3505084,2025-07-27T15:15:33.715625
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis,Leukemia and Lymphoma,2024,10.1080/10428194.2024.2369653,https://experts.mcmaster.ca/display/publication3450503,2025-07-27T15:15:33.715626
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,MM-357 Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients,"Clinical Lymphoma, Myeloma and Leukemia",2024,10.1016/s2152-2650(24)01670-7,https://experts.mcmaster.ca/display/publication3494186,2025-07-27T15:15:33.715627
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,P-063 Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients,"Clinical Lymphoma, Myeloma and Leukemia",2024,10.1016/s2152-2650(24)01966-9,https://experts.mcmaster.ca/display/publication3494184,2025-07-27T15:15:33.715628
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients,"Clinical Lymphoma, Myeloma and Leukemia",2024,10.1016/s2152-2650(24)00957-1,https://experts.mcmaster.ca/display/publication3494185,2025-07-27T15:15:33.715629
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials,BMJ Open,2024,10.1136/bmjopen-2022-068182,https://experts.mcmaster.ca/display/publication3385438,2025-07-27T15:15:33.715630
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Cystoid macular edema prophylaxis in cataract surgery: A protocol for network meta-analysis.,PLoS ONE,2024,10.1371/journal.pone.0314467,https://experts.mcmaster.ca/display/publication3504795,2025-07-27T15:15:33.715631
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology,Value in Health,2023,10.1016/j.jval.2023.09.953,https://experts.mcmaster.ca/display/publication3494187,2025-07-27T15:15:33.715632
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,MSR15 The Impact of Response Assessment Timing on Indirect Treatment Comparisons (ITCS) – A Simulation Study,Value in Health,2023,10.1016/j.jval.2023.09.2074,https://experts.mcmaster.ca/display/publication3494188,2025-07-27T15:15:33.715633
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis,"Clinical Lymphoma, Myeloma and Leukemia",2023,10.1016/s2152-2650(23)01377-0,https://experts.mcmaster.ca/display/publication3494190,2025-07-27T15:15:33.715634
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,POSTER: MCL-373 Unmet Need in Relapsed/Refractory (RR) Mantle Cell Lymphoma (MCL) Post-Bruton Tyrosine Kinase Inhibitor (BTKi): Systematic Literature Review and Meta-Analysis,"Clinical Lymphoma, Myeloma and Leukemia",2023,10.1016/s2152-2650(23)00776-0,https://experts.mcmaster.ca/display/publication3494189,2025-07-27T15:15:33.715635
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Theory and practice of Bayesian and frequentist frameworks for network meta-analysis,BMJ Evidence-Based Medicine,2023,10.1136/bmjebm-2022-111928,https://experts.mcmaster.ca/display/publication2315252,2025-07-27T15:15:33.715636
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) POST‐BRUTON TYROSINE KINASE INHIBITOR (BTKI): A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS,Hematological Oncology,2023,10.1002/hon.3165_603,https://experts.mcmaster.ca/display/publication3494192,2025-07-27T15:15:33.715637
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis",Journal of Hematology and Oncology,2023,10.1186/s13045-023-01417-5,https://experts.mcmaster.ca/display/publication2980732,2025-07-27T15:15:33.715638
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis,"Clinical Lymphoma, Myeloma and Leukemia",2023,10.1016/j.clml.2022.11.002,https://experts.mcmaster.ca/display/publication2658796,2025-07-27T15:15:33.715639
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis,Clinical Orthopaedics and Related Research,2022,10.1097/corr.0000000000002219,https://experts.mcmaster.ca/display/publication2433833,2025-07-27T15:15:33.715640
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.",Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.e19062,https://experts.mcmaster.ca/display/publication3245942,2025-07-27T15:15:33.715641
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Treatment outcomes for newly diagnosed, untreatedTP53-mutated acute myeloid leukemia: A systematic review and meta-analysis.",Journal of Clinical Oncology,2022,10.1200/jco.2022.40.16_suppl.e19020,https://experts.mcmaster.ca/display/publication3245943,2025-07-27T15:15:33.715642
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,POSC427 Platform Trials: A Path to Efficient Decision Making and Faster Drug Approvals for Health Technology Assessment Bodies,Value in Health,2022,10.1016/j.jval.2021.11.1346,https://experts.mcmaster.ca/display/publication3245944,2025-07-27T15:15:33.715643
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART,BMC Medical Research Methodology,2021,10.1186/s12874-021-01254-5,https://experts.mcmaster.ca/display/publication1965105,2025-07-27T15:15:33.715644
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT),PharmacoEconomics (Auckland),2021,10.1007/s40273-021-01039-0,https://experts.mcmaster.ca/display/publication1983995,2025-07-27T15:15:33.715644
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists,European Journal of Health Economics,2021,10.1007/s10198-021-01286-0,https://experts.mcmaster.ca/display/publication1966330,2025-07-27T15:15:33.715645
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Clinical Trial Data Sharing for COVID-19–Related Research,Journal of Medical Internet Research,2021,10.2196/26718,https://experts.mcmaster.ca/display/publication1963558,2025-07-27T15:15:33.715647
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes,Journal of Comparative Effectiveness Research,2021,10.2217/cer-2020-0137,https://experts.mcmaster.ca/display/publication2658699,2025-07-27T15:15:33.715648
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Reporting and design of randomized controlled trials for COVID-19: A systematic review,Contemporary Clinical Trials,2021,10.1016/j.cct.2020.106239,https://experts.mcmaster.ca/display/publication1940270,2025-07-27T15:15:33.715649
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents,Journal of the Endocrine Society,2021,10.1210/jendso/bvaa155,https://experts.mcmaster.ca/display/publication1941464,2025-07-27T15:15:33.715650
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis",EClinicalMedicine,2020,10.1016/j.eclinm.2020.100573,https://experts.mcmaster.ca/display/publication1939396,2025-07-27T15:15:33.715651
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Conservative Intervention Strategies for Adult Cancer-Related Lymphedema: A Systematic Review and Network Meta-Analysis,Oncology Nursing Forum,2020,10.1188/20.onf.e171-e189,https://experts.mcmaster.ca/display/publication1923169,2025-07-27T15:15:33.715652
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,PNS18 IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT),Value in Health,2020,10.1016/j.jval.2020.04.1029,https://experts.mcmaster.ca/display/publication2579408,2025-07-27T15:15:33.715653
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"An Exploratory Analysis of Predictors of Concordance Between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta",Healthcare Policy,2020,10.12927/hcpol.2020.26128,https://experts.mcmaster.ca/display/publication1698147,2025-07-27T15:15:33.715653
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis,EClinicalMedicine,2020,10.1016/j.eclinm.2019.12.007,https://experts.mcmaster.ca/display/publication1688096,2025-07-27T15:15:33.715654
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries,Infection and Drug Resistance,2020,10.2147/idr.s288399,https://experts.mcmaster.ca/display/publication1943576,2025-07-27T15:15:33.715655
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols",Trials,2019,10.1186/s13063-019-3664-1,https://experts.mcmaster.ca/display/publication1665447,2025-07-27T15:15:33.715656
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D),Value in Health,2019,10.1016/j.jval.2019.09.885,https://experts.mcmaster.ca/display/publication3245950,2025-07-27T15:15:33.715657
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS,Value in Health,2019,10.1016/j.jval.2019.09.2178,https://experts.mcmaster.ca/display/publication3245951,2025-07-27T15:15:33.715658
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Reporting of master protocols towards a standardized approach: A systematic review,Contemporary Clinical Trials Communications,2019,10.1016/j.conctc.2019.100406,https://experts.mcmaster.ca/display/publication1654087,2025-07-27T15:15:33.715659
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"A Profile of Older Adults With a History of Stroke Receiving Home Care in Ontario, Canada",Home Health Care Management and Practice,2019,10.1177/1084822318823731,https://experts.mcmaster.ca/display/publication1697803,2025-07-27T15:15:33.715660
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Health Utility Book (HUB)–Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer,MDM Policy and Practice,2019,10.1177/2381468319852594,https://experts.mcmaster.ca/display/publication1663230,2025-07-27T15:15:33.715662
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy",Clinical Research in Cardiology,2019,10.1007/s00392-018-1379-z,https://experts.mcmaster.ca/display/publication3245952,2025-07-27T15:15:33.715662
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)",Medical decision making,2019,10.1177/0272989x19837969,https://experts.mcmaster.ca/display/publication1634805,2025-07-27T15:15:33.715664
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,How do financial (dis)incentives influence health behaviour and costs? Protocol for a systematic literature review of randomised controlled trials,BMJ Open,2019,10.1136/bmjopen-2018-024694,https://experts.mcmaster.ca/display/publication1639835,2025-07-27T15:15:33.715665
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma,Cancer Treatment Reviews,2019,10.1016/j.ctrv.2019.02.001,https://experts.mcmaster.ca/display/publication1630075,2025-07-27T15:15:33.715666
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Interventions to improve birth outcomes of pregnant women living in low- and middle-income countries: a systematic review and network meta-analysis,Gates Open Research,2019,10.12688/gatesopenres.13081.2,https://experts.mcmaster.ca/display/publication1936699,2025-07-27T15:15:33.715667
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis,Schizophrenia Research and Treatment,2018,10.1155/2018/1543034,https://experts.mcmaster.ca/display/publication1545901,2025-07-27T15:15:33.715668
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Deficiencies in addressing effect modification in network meta-analyses: a meta-epidemiological survey,Journal of Clinical Epidemiology,2017,10.1016/j.jclinepi.2017.06.004,https://experts.mcmaster.ca/display/publication829123,2025-07-27T15:15:33.715669
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis,Diabetes Therapy,2017,10.1007/s13300-016-0217-4,https://experts.mcmaster.ca/display/publication3245953,2025-07-27T15:15:33.715669
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review,BMC Pediatrics,2016,10.1186/s12887-016-0710-y,https://experts.mcmaster.ca/display/publication794752,2025-07-27T15:15:33.715670
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,What Is the Link Between Corporal Punishment and Child Physical Abuse?,Journal of Family Violence,2015,10.1007/s10896-014-9663-9,https://experts.mcmaster.ca/display/publication2658700,2025-07-27T15:15:33.715671
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Highlights of the Canadian Frailty Network (CFN) Highly Qualified Personnel Poster Session,Canadian Geriatrics Journal,,10.57700/cgj.22.369,https://experts.mcmaster.ca/display/publication1972012,2025-07-27T15:15:33.715672
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,Interventions to improve birth outcomes of pregnant women living in low- and middle-income countries: a systematic review and network meta-analysis,Gates Open Research,,10.12688/gatesopenres.13081.1,https://experts.mcmaster.ca/display/publication3245945,2025-07-27T15:15:33.715674
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,P1204: AXICABTAGENE CILOLEUCEL VEIN‐TO‐VEIN TIME IN TRIAL OR REAL‐WORLD SETTINGS VS OTHER CAR T‐CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSIS,HemaSphere,,10.1097/01.hs9.0000971712.73401.70,https://experts.mcmaster.ca/display/publication3494191,2025-07-27T15:15:33.715675
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,"P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS",HemaSphere,,10.1097/01.hs9.0000845096.01949.78,https://experts.mcmaster.ca/display/publication3245941,2025-07-27T15:15:33.715676
Michael Zoratti,zorattmj@mcmaster.ca,journal_articles,P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS,HemaSphere,,10.1097/01.hs9.0000845980.88839.7d,https://experts.mcmaster.ca/display/publication3245940,2025-07-27T15:15:33.715677
Michael Zoratti,zorattmj@mcmaster.ca,conferences,"Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naive, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.",Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2472487,2025-07-27T15:15:33.715678
Michael Zoratti,zorattmj@mcmaster.ca,conferences,"Treatment outcomes for newly diagnosed, untreatedTP53-mutated acute myeloid leukemia: A systematic review and meta-analysis.",Journal of Clinical Oncology,2022,,https://experts.mcmaster.ca/display/publication2472488,2025-07-27T15:15:33.715679
Michael Zoratti,zorattmj@mcmaster.ca,conferences,IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT),Value in Health,2020,,https://experts.mcmaster.ca/display/publication1914423,2025-07-27T15:15:33.715680
Michael Zoratti,zorattmj@mcmaster.ca,conferences,PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY,Value in Health,2019,10.1016/j.jval.2019.04.165,https://experts.mcmaster.ca/display/publication1658797,2025-07-27T15:15:33.715681
Michael Zoratti,zorattmj@mcmaster.ca,conferences,"PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING",Value in Health,2019,10.1016/j.jval.2019.04.166,https://experts.mcmaster.ca/display/publication1658796,2025-07-27T15:15:33.715682
Michael Zoratti,zorattmj@mcmaster.ca,conferences,PNS88 IMPACT OF PATIENT-TARGETED FINANCIAL INCENTIVES ON HEALTHCARE COSTS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS,Value in Health,2019,10.1016/j.jval.2019.04.1447,https://experts.mcmaster.ca/display/publication1658882,2025-07-27T15:15:33.715683
Michael Zoratti,zorattmj@mcmaster.ca,conferences,A META-EPIDEMIOLOGICAL SURVEY OF THE REPORTING OF EFFECT MODIFICATION IN NETWORK META-ANALYSES,Value in Health,2017,,https://experts.mcmaster.ca/display/publication1342663,2025-07-27T15:15:33.715684
Michael Zoratti,zorattmj@mcmaster.ca,conferences,The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis,Arthritis & Rheumatology,2014,,https://experts.mcmaster.ca/display/publication1367770,2025-07-27T15:15:33.715685
Michael Zoratti,zorattmj@mcmaster.ca,preprints,Clinical Trial Data Sharing for COVID-19–Related Research (Preprint),,2020,10.2196/preprints.26718,https://experts.mcmaster.ca/display/publication3245946,2025-07-27T15:15:33.715686
Michael Zoratti,zorattmj@mcmaster.ca,preprints,Evaluation of effects of public health interventions on COVID-19 transmission for Pakistan: A mathematical simulation study,,2020,10.1101/2020.04.30.20086447,https://experts.mcmaster.ca/display/publication3245947,2025-07-27T15:15:33.715687
Michael Zoratti,zorattmj@mcmaster.ca,preprints,"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols",,2019,10.21203/rs.2.9437/v2,https://experts.mcmaster.ca/display/publication3245949,2025-07-27T15:15:33.715688
Michael Zoratti,zorattmj@mcmaster.ca,preprints,"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols",,2019,10.21203/rs.2.9437/v1,https://experts.mcmaster.ca/display/publication3245948,2025-07-27T15:15:33.715689
